Search Results

There are 1436 results for: content related to: Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment

  1. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

    Journal of Viral Hepatitis

    Volume 19, Issue s2, May 2012, Pages: 1–26, I. M. Jacobson, J.-M. Pawlotsky, N. H. Afdhal, G. M. Dusheiko, X. Forns, D. M. Jensen, F. Poordad and J. Schulz

    Article first published online : 8 MAR 2012, DOI: 10.1111/j.1365-2893.2012.01590.x

  2. You have free access to this content
    HCV Therapeutics: Approved Agents

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 1091A–1168A,

    Article first published online : 15 OCT 2013, DOI: 10.1002/hep.26880

  3. Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans

    Journal of Viral Hepatitis

    Volume 22, Issue 5, May 2015, Pages: 489–495, R. Gidwani, P. G. Barnett, J. D. Goldhaber-Fiebert, S. M. Asch, J. Lo, S. K. Dally and D. K. Owens

    Article first published online : 24 NOV 2014, DOI: 10.1111/jvh.12344

  4. You have free access to this content
    Review article: specifically targeted anti-viral therapy for hepatitis C – a new era in therapy

    Alimentary Pharmacology & Therapeutics

    Volume 32, Issue 1, July 2010, Pages: 14–28, C. M. Lange, C. Sarrazin and S. Zeuzem

    Article first published online : 31 MAR 2010, DOI: 10.1111/j.1365-2036.2010.04317.x

  5. You have full text access to this OnlineOpen article
    Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir

    British Journal of Clinical Pharmacology

    Volume 78, Issue 5, November 2014, Pages: 1043–1049, Mark Johnson, Julie Borland, Shuguang Chen, Paul Savina, Brian Wynne and Stephen Piscitelli

    Article first published online : 20 OCT 2014, DOI: 10.1111/bcp.12428

  6. You have free access to this content
    Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients

    Hepatology

    Volume 50, Issue 6, December 2009, Pages: 1709–1718, Simone Susser, Christoph Welsch, Yalan Wang, Markus Zettler, Francisco S. Domingues, Ursula Karey, Eric Hughes, Robert Ralston, Xiao Tong, Eva Herrmann, Stefan Zeuzem and Christoph Sarrazin

    Article first published online : 4 AUG 2009, DOI: 10.1002/hep.23192

  7. You have free access to this content
    British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013

    HIV Medicine

    Volume 14, Issue S4, November 2013, Pages: 1–71, Writing Group, Dr Ed Wilkins, Dr Mark Nelson, Dr Kosh Agarwal, Ms Dola Awoyemi, Dr Eleanor Barnes, Dr Sanjay Bhagani, Dr Gary Brook, Dr Ashley Brown, Ms Sheena Castelino, Dr Graham Cooke, Prof Martin Fisher, Prof Anna Maria Geretti, Mr Robert James, Dr Ranjababu Kulasegaram, Prof Clifford Leen, Prof David Mutimer, Dr Chloe Orkin, Dr Emma Page, Dr Adrian Palfreeman, Dr Padmasayee Papineni, Dr Alison Rodger and Dr CY William Tong

    Article first published online : 25 OCT 2013, DOI: 10.1111/hiv.12106

  8. You have free access to this content
    Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 54–60, Mitchell L. Shiffman and Rafael Esteban

    Article first published online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02718.x

  9. Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations

    The Journal of Clinical Pharmacology

    Volume 55, Issue 5, May 2015, Pages: 517–524, Sandra Bodeau, Eric Nguyen-Khac, Caroline Solas, Youssef Bennis, Dominique Capron, Gilles Duverlie and Etienne Brochot

    Article first published online : 4 FEB 2015, DOI: 10.1002/jcph.454

  10. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir

    Alimentary Pharmacology & Therapeutics

    Volume 41, Issue 7, April 2015, Pages: 671–685, R. K. Sterling, A. Kuo, V. K. Rustgi, M. S. Sulkowski, T. G. Stewart, J. M. Fenkel, H. El-Genaidi, M. A. Mah'moud, G. M. Abraham, P. W. Stewart, L. Akushevich, D. R. Nelson, M. W. Fried and A. M. Di Bisceglie

    Article first published online : 28 JAN 2015, DOI: 10.1111/apt.13095

  11. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings

    Journal of Viral Hepatitis

    Volume 22, Issue 9, September 2015, Pages: 691–700, A. A. Butt, P. Yan, O. S. Shaikh, M. S. Freiberg, V. Lo Re III, A. C. Justice, K. E. Sherman and for the ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team

    Article first published online : 18 DEC 2014, DOI: 10.1111/jvh.12375

  12. New Pharmacotherapy for Hepatitis C

    Clinical Pharmacology & Therapeutics

    Volume 92, Issue 3, September 2012, Pages: 294–305, D N Assis and J K Lim

    Article first published online : 1 AUG 2012, DOI: 10.1038/clpt.2012.103

  13. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b

    Journal of Viral Hepatitis

    Volume 19, Issue 2, February 2012, Pages: 120–127, J. Vermehren, S. Susser, C. M. Lange, N. Forestier, U. Karey, E. Hughes, R. Ralston, X. Tong, S. Zeuzem and C. Sarrazin

    Article first published online : 1 MAR 2011, DOI: 10.1111/j.1365-2893.2011.01449.x

  14. You have free access to this content
    New HCV therapies on the horizon

    Clinical Microbiology and Infection

    Volume 17, Issue 2, February 2011, Pages: 122–134, J. Vermehren and C. Sarrazin

    Article first published online : 20 JAN 2011, DOI: 10.1111/j.1469-0691.2010.03430.x

  15. You have free access to this content
    Future treatment of patients with HCV cirrhosis

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 113–119, Marc Bourlière, Asma Khaloun, Claire Wartelle-Bladou, Valérie Oules, Isabelle Portal, Souad Benali, Xavier Adhoute and Paul Castellani

    Article first published online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02702.x

  16. You have free access to this content
    Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers

    Hepatology

    Volume 56, Issue 5, November 2012, Pages: 1622–1630, Ellen Hulskotte, Samir Gupta, Fengjuan Xuan, Marga van Zutven, Edward O'Mara, Hwa-Ping Feng, John Wagner and Joan Butterton

    Article first published online : 14 OCT 2012, DOI: 10.1002/hep.25831

  17. You have free access to this content
    Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects

    Journal of Gastroenterology and Hepatology

    Volume 29, Issue 8, August 2014, Pages: 1574–1581, Eric J Lawitz and Fernando E Membreno

    Article first published online : 29 JUL 2014, DOI: 10.1111/jgh.12632

  18. You have free access to this content
    Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial

    Hepatology

    Volume 56, Issue 6, December 2012, Pages: 2106–2115, Sandra De Meyer, Inge Dierynck, Anne Ghys, Maria Beumont, Bjorn Daems, Ben Van Baelen, James C. Sullivan, Douglas J. Bartels, Tara L. Kieffer, Stefan Zeuzem and Gaston Picchio

    Article first published online : 4 DEC 2012, DOI: 10.1002/hep.25962

  19. You have free access to this content
    Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

    Hepatology

    Volume 53, Issue 5, May 2011, Pages: 1742–1751, Jean-Michel Pawlotsky

    Article first published online : 22 APR 2011, DOI: 10.1002/hep.24262

  20. You have free access to this content
    AASLD Abstracts

    Hepatology

    Volume 56, Issue S1, October 2012, Pages: 191A–1144A,

    Article first published online : 1 OCT 2012, DOI: 10.1002/hep.26040